Studies on the contraceptive effect of chlormadinone
Marcinkowski, Z.
Ginekologia Polska 51(5): 453-465
1980
ISSN/ISBN: 0017-0011 PMID: 6157607 Document Number: 156369
The investigations covered 80 women receiving oral contraceptives (43 Chlormadinone and 37 Femigen). The chlormadinone preparation was ingested in a daily dose of 0.5 mg in 43 women, through 351 months with a coefficient of gestations of 6.8 (technique fault 3.4), with a minimum of side effects, without apparent influence on body weight and arterial blood pressure. This preparation caused disturbances of the cycle length (18.4% of cycles) and spotting in the course of the cycle (13.7% of cycles); however, 71% of cycles were free of these disturbances. It was demonstrated that an important role in the mechanism of contraception is played by the changes in cervical mucus and in the endometrium. The Femigen preparation was used by 37 women through 450 months with full contraceptive efficacy (coefficient of gestations, 4.3, due to technique faults, 0). It caused numerous and sometimes troublesome side effects which were observed in 65.1% of cycles in the first 5 months of administration and reduced in the following months to 52.4% of the cycles. While intermenstrual spotting (10.9% of cycles) and amenorrhea (12.4% of cycles) were due to the drug, it did not induce alterations in body weight or blood pressure. The observations suggest that the administration of chlormadinone preparations in a daily dose of 0.5 mg as luteal supplementation is a safe and usable technique of oral contraception, especially when the classic technique is poorly tolerated or contraindications exist as to the administration of estrogen-progestagen compositions. (Author's modified)